Pharmaceutical executives who pitch branded generics to their boards often face the same question: why pour marketing dollars into a […]

The difference between first place and second place in the generic drug market is not measured in prestige. It is

AbbVie collected roughly $114 billion in U.S. Humira revenue before the first biosimilar cleared a path to pharmacy shelves. Allergan

Every brand team runs the same model. The compound patent expires on a known date. You build a 24-month revenue

The expiration date on a blockbuster drug’s primary patent is almost never the date generic competition arrives. Between that printed

Every few years, a mid-size generic manufacturer files a Paragraph IV certification against a blockbuster drug, gets sued by a

Pharmaceutical patent litigation produces more text per dollar at stake than almost any other legal domain. A single Hatch-Waxman case

The conventional wisdom in generic pharmaceuticals is seductive in its simplicity: be first, win big. File first, launch first, collect

Every commercial contract negotiation in pharmaceuticals has a clock running in the background. That clock is the patent expiry date,